PharVision Advisers’s Bain Capital Specialty BCSF Stock Holding History

PharVision Advisers’s Portfolio BCSF Stock Details BCSF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,566	Closed	-$151K	–	710
2025 Q3	$151K	Sell	10,566 -3,273	-24%	-$49.7K	0.08%	572
2025 Q2	$208K	Sell	13,839 -5,090	-27%	-$77.6K	0.3%	191
2025 Q1	$314K	Buy	+18,929	New	+$333K	0.44%	85

Other funds holding BCSF

BCC

Bain Capital Credit Boston, Massachusetts $303M AUM 15.47% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Melia Wealth Tulsa, Oklahoma $207M AUM 13.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCM

Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return

Muzinich & Co New York $293M AUM 18.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PharVision Advisers's BCSF Position: Q4 2025 in Review

PharVision Advisers sold out of Bain Capital Specialty (BCSF) in Q4 2025, closing a stake of 10,566 shares — an estimated $151K sold.

PharVision Advisers first reported a position in BCSF in Q1 2025 and held it in 3 quarters. The position peaked at $314K in Q1 2025. 141 funds tracked by Wall St. Rank hold BCSF as of Q4 2025.

PharVision Advisers reported no remaining Bain Capital Specialty position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 10,566 Bain Capital Specialty shares in Q4 2025, an estimated $151K.
PharVision Advisers first reported a position in Bain Capital Specialty in Q1 2025 and held it in 3 quarters.
PharVision Advisers's Bain Capital Specialty position peaked at $314K in Q1 2025.
141 funds tracked by Wall St. Rank held Bain Capital Specialty as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.